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Objectives: High-risk human papillomavirus (hrHPV) is known to be a represen-
tative cancer-causing agent in the genital and head and neck regions. Many
studies have detected hrHPV DNA in nonsmall cell lung carcinoma. However,
hrHPVeetiologic correlation in nonsmall cell lung carcinoma remains unclear.
This study is designed to determine the prevalence of episomal or integrated
hrHPV DNA in nonsmall cell lung carcinoma among the Korean population.
Methods: Surgically resected nonsmall cell lung carcinoma tissues, including 134
cases of squamous cell carcinoma (SqCC) and 99 cases of adenocarcinoma (ADC),
were examined. In situ hybridization (ISH) for detecting episomal or integrated
hrHPV DNA was performed using the INFORM HPV III Family 16 Probe (B) in the
Ventana-validated assay. Anyplex II HPV28 detection kit based on real-time
polymerase chain reaction was used for HPV DNA detection and genotyping.
Results: All members of the study population were of Korean ethnicity. Episomal
or integrated hrHPV DNA ISH analysis result was negative in all 233 cases. One
SqCC of 89 samples (42 SqCCs and 47 ADCs) was positive for an hrHPV genotype by
Anyplex II HPV28 detection kit.
Conclusion: Our finding did not demonstrate hrHPVeetiologic correlation in
primary lung SqCC and ADC in the Korean population.1. Introduction
Human papillomavirus (HPV) is a double-stranded
DNA virus and is a representative virus known to be an
etiologic agent in both benign and malignant tumors..
ase Control and Prevention.
reativecommons.org/licensThere are more than 100 different types of HPV, of which
cancer-causing types are called “high-riskHPV (hrHPV).”
The cancer-causing roles of hrHPV in uterine cervical
carcinoma and oropharyngeal carcinoma are well estab-
lished [1e3]. Epidemiologic research, clinical research,Published by Elsevier Korea LLC. This is an open access article
es/by-nc-nd/4.0/).
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tionship in head and neck cancer, anal cancer, esophageal
cancer, and lung cancer [4e6]. Based on a series of
epidemiologic changes, a viral etiology has been theorized
as playing a role in lung cancer initiation or evolution.
Many studies have detected HPVDNA in lung cancer and
the possible correlation between lung cancer and HPV has
been suggested [6e8]. However, inconsistent data
regarding HPV DNA detection in lung cancer have been
observed between studies. We considered that the het-
erogeneity of HPV DNA prevalence in lung cancer might
be due to various HPV DNA detection methods as well as
due to variations in geographical study origin and histo-
logical types of cancer. Usually, to detect HPV DNA,
polymerase chain reaction (PCR) inDNAsamples purified
from tissue specimens and in situ hybridization (ISH)
signal amplification in target tissues are used. A strong
advantage of ISH is the direct visualization of HPV in
either the episomal form or an integrated patternwithin the
nuclei of tumor cells in tissues.
The aim of this study is to determine the prevalence
of episomal or integrated hrHPV DNA in malignant
cells of primary lung squamous cell carcinoma (SqCC)
and adenocarcinoma (ADC) among Korean population,
using the INFORM HPV III Family 16 Probe (B) in the
Ventana-validated assay.2. Materials and methods
2.1. Patients and tissue samples
We obtained 233 formalin-fixed, paraffin-embedded
(FFPE) lung samples from 233 patients who underwent
surgical resection at Chungnam National University
Hospital, Daejeon, South Korea, between 1995 and 2010.
The tissues consisted of SqCC (n Z 134) and 99 ADC
(nZ 99) samples. All samples were isolated from lobec-
tomyor pneumonectomy specimens.Clinical recordswere
reviewed. Of these, none of the 233 cases had any known
history of head and neck primary cancer or uterine cervical
cancer. None of the patients had received preoperative
chemotherapy or radiotherapy. The lung cancer stages
were determined according to the American Joint Com-
mittee on Cancer Staging System, Seventh Edition. Clin-
ical data were provided by the National Biobank of Korea,
Chungnam National University Hospital, Daejeon, South
Korea. This study was approved by the Institutional Re-
view Board of Chungnam National University Hospital.
2.2. Tissue microarray construction
All cases were histologically reviewed by two pa-
thologists (K.-H.K. and Y.-M.L.), and the two most
representative areas of viable carcinoma tissue were
selected and marked on the hematoxylin and eosin-
stained slides. To create a tissue microarray (TMA),
tissue columns (diameter, 3.0 mm) were punched from
the original paraffin blocks and inserted into newrecipient paraffin blocks (each containing 30 holes for
tissue columns). Arrays were constructed using two 3-
mm diameter cores per tumor.
2.3. High-risk HPV DNA ISH
All TMA blocks and 20 whole-FFPE SqCC blocks
were used for hrHPV DNA detection. ISH was per-
formed using the Ventana INFORM HPV III Family 16
probe (B) kit (Catalog Number 800-4295; Ventana
Medical System, Inc., Tucson, AZ, USA) according to
the manufacturer’s recommendations on the BenchMark,
Automated Slide Staining System (Ventana Medical
System, Inc.). The INFORM HPV III Family 16 probe
(B) kit is composed of oligonucleotides designed to hy-
bridize with hrHPV genotypes 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, and 66. The positive hrHPV signal
demonstrated either episomal or integrated HPV. The
episomal pattern appears as a large, homogeneous,
globular navy-blue precipitate and the integrative pattern
as a discrete, stippled navy blue nuclear pattern within
the nuclei of neoplastic cells. Five hrHPV-positive cases
of laryngeal SqCC were used as positive controls. Two
pathologists independently reviewed the hrHPV ISH
slides and a consensus was obtained after discussion.
2.4. Detection and genotyping of HPV DNA
DNA was extracted from the whole-FFPE samples of
42 SqCCs and 47 ADCs. FFPE blocks were sectioned in
six 7-mm sections. Total DNA was extracted using the
G-DEX IIc Genomic DNA Extraction Kit according
to manufacturer’s instructions (iNtRON, Gyeonggi-do,
South Korea).
The Anyplex II HPV28 Detection kit (Seegene, Seoul,
South Korea) identifies simultaneously 19 hrHPVs (16,
18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69,
73, and 82) and nine low-risk HPVs (6, 11, 40, 42, 43, 44,
54, 61, and 70). Real-time PCRs were performed on a
CFX96 Real-Time PCR System (Bio-Rad Laboratories,
Hercules, CA, USA) with 20-mL reaction tubes contain-
ing HPV28 primer mix A, which recognizes 14 hrHPV
types or mix B that identifies five hrHPV types and nine
low-risk HPV types, Anyplex Master Mix (Seegene), and
genomic DNA purified from specimen. For each run,
positive controls of all HPV-type plasmid constructs were
included along with a nontemplate control. Results were
automatically analyzed in Seegene Viewer version 2.0
(Seegene, Seoul, South Korea) [9,10].3. Results
We investigated 233 lung carcinoma samples. The
demographics of the study patients are presented in
Table 1. All members of the study population were of
Korean ethnicity. hrHPV DNA ISH analysis was nega-
tive in all 233 TMA samples and 20 whole-FFPE SqCC
samples (Figure 1).
Table 1. Demographics of the lung cancer patients (N Z 233).
Squamous cell carcinoma (n Z 134) Adenocarcinoma (n Z 99)
Male:Female 125:9 48:51
Age (y) 42e93 (65.78) 23e85 (65.35)
Never-smoker 40 (29.9) 68 (68.7)
Pathologic TNM stage
I 65 (48.5) 52 (52.5)
II 42 (31.3) 23 (23.2)
III 27 (20.1) 24 (24.2)
IV 0 (0.0) 0 (0.0)
Data are presented as n (%) or range (mean). TNM Z tumor, node, and metastasis.
Figure 1. Squamous cell carcinoma. (A) A laryngeal squamous cell carcinoma positive for high-risk human papillomavirus
(hrHPV). (B) A lung squamous cell carcinoma-negative in situ hybridization for hrHPV (Scale bar: 60 mm).
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47 ADCs were analyzed using the Anyplex II HPV28
Detection kit (Seegene) for detection and genotyping of
HPV DNA. Only one SqCC of the total 89 samples (42
SqCCs and 47 ADCs) was positive for an HPV geno-
type, namely, hrHPV genotype 31. However, this posi-
tive case showed no signal amplification when subjected
to HPV DNA ISH analysis using a whole-FFPE block
sample.4. Discussion
No hrHPV DNA was demonstrated in our study,
which included 134 SqCC cases and 99 ADC cases of
the lung, in hrHPV DNA ISH analysis using Ventana
INFORM HPV III Family 16 Probe (B). Other recent
studies also failed to detect hrHPV DNA [Ventana
INFORM HPV III Family 16 Probe (B)] and HPV E6/
E7 messenger RNA (mRNA) using the RNAscope HPV
kit (Advanced Cell Diagnostics Inc., Hayward, CA,
USA) in primary lung SqCC and ADC [11,12]. Several
other studies consistently have shown no presence of
HPV16 E6/E7 mRNA by reverse transcription-PCR
(RT-PCR) in primary lung SqCCs and ADCs [13,14].
The most commonly used method to detect HPV
DNA is PCR in DNA purified from specimens. How-
ever, the sole finding of HPV DNA using PCR is not
sufficient to prove the carcinogenic role of HPV in thedevelopment of cancer [12,15]. Compared with PCR,
the HPV DNA ISH method permits visualization of
HPV DNA signals using light microscopy to determine
the prevalence of episomal or integrated HPV DNA in
tissue specimens. To confirm that a tumor is caused by
HPV, detecting the mRNA transcripts of HPV E6 and
E7 viral oncogenes is necessary. Although detecting
mRNA from FFPE tissue using RT-PCR is challenging,
the RNAscope HPV kit (Advanced Cell Diagnostics
Inc.) for RNA ISH probes complementary to E6/E7
mRNA permits direct visualization of viral transcripts in
tissues [16]. Previous studies comparing HPV DNA ISH
and RNA ISH assay found a high concordance rate in
head and neck SqCC and nonsmall cell lung carcinoma
[4,12]. Therefore, HPV DNA ISH is a feasible detection
method in the clinical laboratory to prove that HPV is
the etiologic factor for tumor development.
An international pooled analysis showed that the
highest prevalence of HPV16/18 DNA was observed in
South and Central America, followed by Asia, North
America, and Europe [7]. Our result does not support the
previous studies showing a significantly higher detection
rate of HPV in lung carcinoma in the Asian population
than in the Australian, European, and North American
populations [6,7,17,18]. The discordant results could be
explained by the different detection methods.
In conclusion, our results are in concordance with
previous studies in which neither episomal nor inte-
grated hrHPV DNA was detected in primary lung SqCC
High-risk HPV in nonsmall cell lung carcinoma 359and ADC in hrHPV DNA ISH using Ventana INFORM
HPV III Family 16 Probe (B). Thus, a causal relation-
ship between hrHPV infection and carcinogenesis of
primary lung SqCC and ADC was not demonstrated in
the Korean population.Conflicts of interest
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